Recurrent cardiac arrest due to eosinophilia-related coronary vasospasm successfully treated by benralizumab

Affiliations

• ¹ National Reference Center for Hypereosinophilic Syndromes (CEREO), France; Department of Internal Medicine, Hôpital Foch, Suresnes, France. Electronic address: [email protected].
• ² Sorbonne Université, Assistance Publique-Hôpitaux de Paris (APHP), Hôpital La Pitié-Salpêtrière, Service de Médecine Intensive-Réanimation, Paris, France; Sorbonne Université, APHP, Hôpital La Pitié-Salpêtrière, Institut E3M, Service de Médecine Interne 2; Centre de Référence National Lupus Systémique, Syndrome des Anticorps Anti-phospholipides et Autres Maladies Auto-Immunes Systémiques Rares, Paris, France; Sorbonne Université, INSERM, UMRS_1166-ICAN, Institut de Cardiométabolisme et Nutrition (ICAN), Paris, France.
• ³ Department of Cardiology, Centre Hospitalier de Versailles, Le Chesnay-Rocquencourt, France.
• ⁴ National Reference Center for Hypereosinophilic Syndromes (CEREO), France; Clinical Research Department, Hôpital Foch, Suresnes, France.
• ⁵ National Reference Center for Hypereosinophilic Syndromes (CEREO), France; Université de Lille, CHU Lille, Institut d'Immunologie, Lille, France.
• ⁶ National Reference Center for Hypereosinophilic Syndromes (CEREO), France; Université Paris Saclay, Department of Internal Medicine, Hôpital Ambroise Paré, Boulogne-Billancourt, France.
• ⁷ National Reference Center for Hypereosinophilic Syndromes (CEREO), France; Department of Respiratory Medicine, Hôpital Foch, Suresnes, France.